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Localization of the catalytic activity in restrictocin molecule by deletion
mutagenesis
Surendra K. Nayak, Shveta and Janendra K. Batra
Immunochemistry Laboratory, National Institute of Immunology, New Delhi, India
Restrictocin, produced by the fungus Aspergillus restrictus, is a highly specific ribonucleolytic toxin which
cleaves a single phosphodiester bond between G4325 and A4326 in the 28S rRNA. It is a nonglycosylated,
single-chain, basic protein of 149 amino acids. The putative catalytic site of restrictocin includes Tyr47, His49,
Glu95, Arg120 and His136. To map the catalytic activity in the restrictocin molecule, and to study the role
of N- and C-terminus in its activity, we have systematically deleted amino-acid residues from both the
termini. Three N-terminal deletions removing 8, 15 and 30 amino acids, and three C-terminal deletions lacking 4,
6, and 11 amino acids were constructed. The deletion mutants were expressed in Escherichia coli, purified to
homogeneity and functionally characterized. Removal of eight N-terminal or four C-terminal amino acids
rendered restrictocin partially inactive, whereas any further deletions from either end resulted in the complete
inactivation of the toxin. The study demonstrates that intact N- and C-termini are required for the optimum
functional activity of restrictocin.
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Restrictocin is a ribosome-inactivating protein toxin, produced
by the fungus Aspergillus restrictus, which is grouped under a
class of protein toxins termed ribotoxins [1]. a-Sarcin and
mitogillin are two other members of the ribotoxin family that
are produced by different strains of Aspergillus and restriction
and mitogillin share 85% homology with a-sarcin [2]. The
cytotoxic activity of ribotoxins is due to their ability to inhibit
eukaryotic protein synthesis, as a result of their ribonucleolytic
effect on the 28S ribosomal RNA [3,4]. The ribotoxins act as
highly specific ribonucleases cleaving a single phosphodiester
bond between G4325 and A4326 in the 28S rRNA [3,5±7], in a
12 nucleotide purine-rich stretch, which is conserved in large
subunit ribosomal RNA of almost all living species [8]. The
cleavage of the 28S rRNA releases a 400 nucleotide long
fragment from the 3 0 end, known as the a-fragment [5]. Once
the 28S rRNA is cleaved by these toxins, EF-1 dependent
binding of aminoacyl tRNA and the GTP-dependent binding of
EF-2 to the ribosomal site is impaired [2,3,9,10] which causes
the total collapse of the translation machinery leading to the
death of the cell. The ribotoxins have great potential to be
utilized in the construction of immunotoxins for targeted
therapy of various diseases. Immunoconjugates and recombi-
nant chimeric toxin have been made with restrictocin that have
been found to be active on various tumor cell lines [11±15].
Restrictocin is a nonglycosylated, single-chain, basic protein
of 149 amino acids [1]. It has four cysteine residues at positions
5, 75, 131 and 147 that are involved in the formation of two
disulfide bridges between residues 5±147 and 75±131 [1]. We
have recently reported that none of the four cysteine residues is
directly involved in restrictocin catalysis, and presence of any
one of the two disulfide bonds is absolutely essential and
sufficient to maintain the enzymatically active conformation of
restrictocin, however, for maintaining the unique stability
displayed by the native toxin, both disulfide bonds are required
[16].
The structural core in restrictocin closely resembles that in
RNase T1, a guanine-specific ribonuclease produced by
Aspergillus oryzae, suggesting that they have similar catalytic
mechanisms, however, restrictocin contains long connecting
loops which have been proposed to be important for the unique
substrate specificity of this protein [17]. The docking model of
the NMR structure of a 29-mer RNA substrate analog with
restrictocin crystal structure has indicated that structural
elements involved in RNA substrate binding include a landing
platform comprising of loops L2 and a lysine rich loop L4, and
a positively charged ridge in loop domain L3 [17]. It has been
proposed that specific interaction between G4319 and the
lysine-rich loop may be responsible for the substrate specificity
of restrictocin [17]. Deletion of K106-K113 in L4 of mitogillin
has been shown to result in the loss of substrate specificity [18].
Kao and Davies [19] on the basis of deletion mutagenesis in
mitogillin have postulated that the specificity of ribotoxins is
the result of natural genetic engineering in which the ribosomal
targeting elements of ribosome-associated proteins were
inserted into nonessential regions of T1-like ribonucleases.
Based on structural and sequence homology studies Tyr47,
His49, Glu95, Phe96, Pro97, Arg120 and His136 have been
proposed to be in the active site of restrictocin [17,20]. We have
shown that His49 is involved in the target recognition activity
of restrictocin [21]. Earlier, mutation of His136 in restrictocin
and His137 in a-sarcin have been shown to completely
inactivate the toxins [22,23], whereas mutation of Glu95 in
restrictocin rendered the toxin partially inactive [22]. Kao et al.
[24] have carried out chemical mutagenesis in mitogillin, and
shown that His49, Glu95, Arg120 and His136 are important for
catalysis by the toxin.
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In the construction of chimeric toxins, a small toxin is
desirable as it provides better folding of the chimeric molecule
and results in their better penetration into the target cells, and
lower antigenicity in the foreign host. To obtain the smallest
biologically active derivative of a protein, it is important to map
and localize the functional activity in the molecule. In the
current study, an attempt has been made to localize region(s)/
domain(s) in restrictocin essential for its catalytic activity. In
order to study the involvement of N- and C-termini in
restrictocin catalysis, systematic deletions of amino-acid
residues from both the termini were carried out. Three
N-terminal deletions removing 8, 15 and 30 amino acids and
three deletion mutants from the C-terminus lacking 4, 6, and 11
amino acids were constructed. The deletion mutants were
expressed and purified from E. coli and functionally charac-
terized. The study demonstrates that intact N- and C-termini are
required for the optimum functional activity of restrictocin.
E X P E R I M E N T A L P R O C E D U R E S
Construction of deletion mutants of restrictocin
The plasmid pRest, containing restrictocin gene in a T7
promoter-based E. coli expression vector was used as the
template to amplify the desired region of restrictocin by PCR
while inserting initiation codon and termination codon at
appropriate locations to construct the deletion mutants [25]. For
deleting 8, 15, and 30 amino acids from N-terminus, fragment
of restrictocin gene was amplified using 5 0 primers from the
appropriate region containing NdeI restriction site and ATG
initiation codon placed upstream of the codons for amino-acid
residues 9, 16, and 31, respectively, by PCR [26]. The 5 0
primers SD-8, SD-15, and SD-30 were used to construct the
deletion mutants D1±8, D1±15 and D1±30, respectively
(Table 1). The common 3 0 primer, JRS-3 contained EcoRI
site after the stop codon and annealed to the 3 0 end of
restrictocin. For the construction of C-terminal deletion
mutants, D146±149, D144±149, and D139±149 restrictocin
gene was similarly amplified with stop codon and EcoRI site
placed down stream of codons for amino-acid residues 145,
143, and 138 by PCR using primers S3 0D4, S3 0D6, and
S3 0D11, respectively, along with a common 5 0 primer, XUP
that anneals to the sequences upstream to restrictocin gene in
the vector (Table 1). The purified amplified fragments were
digested with NdeI and EcoRI and ligated to pVex11 digested
with the same enzymes. pVex11 is a pET-derived T7 promoter-
based expression vector with a bacterial and phage F1 origin of
replication, kindly provided to us by V.K. Chaudhary
(University of Delhi, India). The mutations were confirmed
by DNA sequencing using the dideoxy chain termination
method [27].
Isolation and purification of the proteins from the inclusion
bodies
Restrictocin and the various mutants were expressed in BL21
(lDE3) strain of E. coli. Bacterial cells were transformed with
the desired construct and grown in Super broth (pH 7.2) [16],
containing 100 mg´mL21 ampicillin, at 37 8C with shaking. At
a D600 of 2.0, the cells were induced with 1 mm isopropyl thio-
b-d-galactoside, and harvested 2 h later. The recombinant
proteins were purified from the inclusion bodies using the
procedure described by Buchner et al. [28]. The total cell pellet
was resuspended in 50 mm Tris/HCl pH 7.4 containing 20 mm
EDTA and incubated at room temperature for 1 h after adding
0.2 mg´mL21 lysozyme. At the end of the incubation, NaCl and
Triton X-100 were added to a final concentration of 0.4 m and
2%, respectively, and the suspension was further incubated at
room temperature for 30 min. The mixture was centrifuged at
13 000 g and the pellet was repeatedly washed in 50 mm
Tris/HCl pH 7.4 containing 20 mm EDTA. The pellet was
dissolved in 6 m guanidine hydrochloride and incubated for 2 h
at room temperature followed by centrifugation at 50 000 g at
4 8C, for 30 min. The concentration of denatured protein in the
supernatant was adjusted to 10 mg´mL21 with 6 m guanidine
hydrochloride, and it was reduced by adding 65 mm dithio-
erythritol and incubating at room temperature for 2 h.
Renaturation was carried out by diluting the denatured protein,
100-fold, in a buffer consisting of 0.1 m Tris/HCl pH 8.0, 0.5 m
l-arginine-HCl, 0.9 mm GSSG, and 0.2 mm EDTA. After
incubating at 10 8C for 48 h, the renatured material was
dialyzed against 20 mm Mes, pH 5.0, containing 100 mm urea,
loaded on a S-Sepharose column, and eluted with a NaCl
gradient 0±1 m in 20 mm Mes buffer (pH 5.0) using an FPLC
system. Relevant fractions were pooled, concentrated and
purified to homogeneity by gel filtration chromatography on
a TSK 3000 column (Pharmacia LKB) in NaCl/Pi.
CD-spectral analysis of restrictocin and its mutants
To analyse the secondary structure, restrictocin or the mutants
were diluted to 67 mg´mL21 in 10 mm sodium phosphate buffer
(pH 7.0), and CD spectra were recorded in the far-UV range
(200±250 nm) at room temperature, using a Jasco J710
spectropolarimeter. A cell with a 1-cm optical path was used
to record the spectra at a scan speed of 50 nm´min21 with a
sensitivity of 50 mdeg and a response time of 1 s. The sample
compartment was purged with nitrogen, and spectra were
averaged over 10 scans. The results are presented as mean
residue ellipticity.
Specific ribonucleolytic activity assay
To evaluate the ability of restrictocin and its mutants to
specifically cleave the 28S rRNA and produce the characteristic
400 nucleotide long a-fragment, rabbit reticulocyte lysate was
treated with different concentrations of the toxin or the mutants
as described earlier [21]. Total RNA was isolated using the
Trizol reagent (Gibco BRL) as recommended by the manu-
facturer and dissolved in a buffer containing 32% formamide,
4 mm EDTA, 0.04% xylene cyanol, and 0.04% bromophenol
blue. The samples were heated at 60 8C for 10 min and
Table 1. Primers used for the construction of deletion mutants of
restrictocin. The letters in small case represent the nucleotides mutated and
the underlined sequence denotes the restriction sites created in the primer.
Primer Sequence
XUP 5 0-ACTCACTATAGGGAGACCAC-3 0
JRS-3 5 0-TGTTAGCAGCCGAATTCAATGAGAACACAG-3 0
SD-8 5 0-ACATGCATCcAtatgCAGCTGAATCCC-3 0
SD-15 5 0-AATCCCAAGcatAtgAAATGGGAAGAC-3 0
SD-30 5 0-CAAGCCAAAcatatgAGCAACTCCCAC-3 0
S3 0D4 5 0-CTAATGAGgAattcaTCTCAAGTCTCC-3 0
S3 0D6 5 0-AGAACACAGaaTtcAGTCTCCCTGATT-3 0
S3 0D11 5 0-CAAGTCTCCCTGaaTtCaCCGCTGATGGGC-3 0
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analyzed on 2% agarose gels. The RNA was visualized by
ethidium bromide staining.
Assay for in vitro protein synthesis
Rabbit reticulocyte lysate was used to assay the ribonucleolytic
activity of restrictocin and its mutants by investigating their
effect on in vitro protein synthesis. Reticulocyte lysate was
prepared from rabbit blood [29], and assay was carried out as
previously described [30]. Rabbit reticulocyte lysate was
treated with different concentrations of various proteins at
30 8C for 1 h and incorporation of [3H]leucine, in the newly
synthesized proteins, was quantitated. Activity was expressed
as percent of control, where no toxin was added.
Cytotoxic activity of restrictocin and its mutants
To assess the cytotoxic activity of restrictocin and its deletion
mutants, HeLa cells permeabilized by adenovirus-infection
were used as described [31]. Adenovirus was propagated in
HEK 293 cells. The HEK 293 cells were grown to a monolayer
in a T25 flask in MEM containing 10% fetal bovine serum. The
monolayer was washed twice with MEM to remove the fetal
bovine serum and inoculated with adenovirus stock in 2 mL
MEM. The cells were incubated at 37 8C for 1 h for infection to
occur and after one wash with MEM, were grown in 3±4 mL of
MEM until cytopathic effects were visible in the monolayer.
The virus was extracted into the medium by lysing the cells by
freezing and thawing. The lysed cell suspension was centri-
fuged at 1500 g for 10 min at 4 8C. The clear supernatant
contained the virus, which was titrated and used for the
cytotoxicity assay. To titrate the virus, HeLa cells, grown in 96
well plates as described below, were incubated with various
dilutions of adenovirus at 37 8C for 5 h followed by 2 h pulse
with [3H]leucine. The cells were harvested onto filtermats and
radioactivity measured using a b-plate counter. The minimum
dilution of the virus, that had no effect or marginal effect on
protein synthesis of the cells, was used for infection in the
cytotoxicity assays.
For the cytotoxicity assay, HeLa cells were grown in RPMI
1640 containing 10% fetal bovine serum at a density of 2  104
cells per well in 96 well culture plates for 12 h at 37 8C. The
medium was replaced with leucine free RPMI containing 1%
fetal bovine serum. Adenovirus and different dilution of
restrictocin or its mutants in 0.2% HSA were added to the
cells and incubated for 5 h. The cells were labeled with 0.1 mCi
[3H]leucine per well for 2 h at 37 8C, harvested onto filtermats
and counted using Pharmacia LKB b-plate counter to estimate
the incorporation of the [3H]leucine in the newly synthesized
proteins. Activity was expressed as percentage of control where
no toxin was added to the cells.
Stability of proteins in in vitro translation assay
Various proteins (5 mg) were incubated with rabbit reticulocyte
lysate and the other reaction components for the in vitro
translation assay for 1 h at 30 8C. At the end of the incubation,
restrictocin and its mutants were immunoprecipitated, by
incubating at 4 8C for 1 h, with 50 mg of a polyclonal
antirestrictocin antibody in NaCl/Pi containing 0.05%
Tween 20. S. aureus cell suspension (Sigma) was added to
the reaction to a final concentration of 1.5% and the mixture
was further incubated at 4 8C for 1 h. The precipitated proteins
were recovered by centrifugation and the pellets, after
washing three times with NaCl/Pi /Tween, were dissolved in
the SDS/PAGE gel-loading buffer. The samples were
electrophoresed on a 14% polyacrylamide gel, transferred
onto the nitrocellulose paper and probed with a polyclonal
antirestrictocin antibody.
General methods
The purified proteins were analysed by SDS/PAGE as described
by Laemmli using 12.5% gels [32], and visualized by staining
the gels with Coomassie brilliant blue. For Western blotting, the
proteins were resolved on SDS-polyacrylamide gels, transferred
onto the nitrocellulose membrane, and detected using a
polyclonal antirestrictocin antibody. Protein concentrations
were measured by the Bradford's method [33].
R E S U L T S
Construction of deletion mutants of restrictocin
To investigate the role of N-terminus in restrictocin catalysis,
three deletion mutants were constructed by PCR. Mutations
were confirmed by DNA sequencing. A diagramatic represen-
tation of these truncated versions of restrictocin is presented in
Fig. 1. All the three N-terminal mutants lack Cys5 and hence
lack the outer disulfide, however, they have all the known and
predicted essential residues intact.
Three C-terminal mutants, D146±149, D144±149, D139±149,
were constructed, which, respectively, have 4, 6, and 11 amino
acids deleted from the carboxyl end of restrictocin. The
deletions and incorporation of stop codon were confirmed by
DNA sequencing. All the deletion mutants thus made lack
Cys147 and hence the Cys5±Cys147 disulfide is missing in all
of them (Fig. 1).
Fig. 1. A diagramatic representation of various deletion mutants of
restrictocin.
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Expression and purification
The deletion mutants of restrictocin were expressed in
BL21(lDE3) strain of E. coli, and were localized in the
inclusion bodies like restrictocin. The recombinant proteins
from the inclusion bodies were denatured in guanidine
hydrochloride and renatured in a glutathione-based refolding
buffer. The renatured material after dialysis was loaded
onto a S-Sepharose cation exchange column. The mutants
like the native toxin eluted at 0.6 m sodium chloride from
the S-Sepharose column. The relevant fractions were pooled
and further purified using a TSK gel filtration column to obtain
the monomeric forms of the proteins. The purified preparations
of mutants gave single bands on SDS/PAGE (Fig. 2A,B). The
size of the mutants was smaller than the native toxin
corresponding to the number of amino acids deleted. All the
mutants and the native toxin reacted equally well with a
polyclonal antibody raised against restrictocin as shown in
Western blots (Fig. 2C,D).
Structural characterization of mutants by circular dichroism
The effect of the N- and C-terminal deletions on the secondary
structure of restrictocin was studied by far-UV CD spectral
analysis of the purified mutants. The mean residue ellipticity
curves of the mutants have been compared with that of
restrictocin (Fig. 3). There were significant differences
observed between the mean residue ellipticity curves of the
native toxin and the N-terminal deleted versions of the toxin.
There was a substantial decrease in the helix content of the
mutants indicating a reduced secondary structure and among
the three, D1±8 had a relatively more compactly folded
structure (Fig. 3A). This indicated that truncation of restric-
tocin from the N-terminus by even as few as eight residues
causes major alterations in the secondary structure of the toxin
molecule.
The mean residue ellipticity curves of the C-terminal
truncated molecules were not remarkably different than that
of restrictocin (Fig. 3B). Both D146±149 and D144±149
mutants had a a + b conformation similar to restrictocin
(Fig. 3B).
Effect of deletions on the specific ribonucleolytic activity of
restrictocin
Restrictocin specifically cleaves a single phosphodiester bond
between G4325 and A4326 to generate a 400-nucleotide
fragment from the 3 0 end of the large ribosomal RNA, known
as the a-fragment. To evaluate the effect of deletions on the
specific ribonucleolytic activity of restrictocin rabbit reticulo-
cyte lysate was treated with restrictocin and its truncated
versions, and the total RNA was analyzed on gel to detect the
production of the a-fragment. The mutant D1±8 was found
to be partially active as it produced the a-fragment at a
much higher concentration compared to restrictocin
(Fig. 4A). D1±15 and D1±30 were both inactive and did
Fig. 2. SDS/PAGE and Western blot analysis of restrictocin and its
deletion mutants. SDS/PAGE analysis of the N-terminal (A) and C-
terminal (B) deletion mutants of restrictocin. The purified proteins were
subjected to SDS/PAGE (12.5%) under reducing condition and stained with
Coomassie blue. Western blot analysis of N-terminal (C) and C-terminal
(D) deletion mutants using antibody raised against restrictocin. The
different lanes in (C) and (D) correspond, respectively, to the same proteins
as in (A) and (B).
Fig. 3. CD spectral analysis of restrictocin
mutants. (A) CD spectra of N-terminal deletion
mutants of restrictocin. The CD spectra of
restrictocin (Ð), D1±8 (---), D1±15 (-´-´-),
and D1±30 (´´´) were recorded in the far-UV
region (200±250 nm) at 25 8C. The spectra
are presented as mean residue ellipticity (MRE),
expressed in degree´cm2´dmol21  1023.
(B) CD spectra of C-terminal mutants. The
spectra of restrictocin (Ð), D146±149 (---),
D144±149 (-´-´-), and D139±149 (´´´) were
obtained as in (A).
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not produce the a-fragment even at 100 mg´mL21 concen-
tration (Fig. 4A). Thus, removal of eight N-terminal amino-
acid residues rendered the toxin partially inactive while
removal of 15 or more residues made it completely inactive
in its ribonucleolytic activity. The C-terminal mutant
D146±149, with the smallest deletion of four amino-acid
residues, was partially active and produced a faint a-fragment
at a higher concentration compared to restrictocin (Fig. 4B).
The deletion mutants D139±149 and D144±149 failed to cleave
the ribosomal RNA even at 10 times higher concentration than
the native toxin (Fig. 4B).
Effect of deletions on in vitro protein synthesis inhibitory
activity of restrictocin
The ability of the restrictocin mutants to inhibit protein
synthesis was tested in a rabbit reticulocyte lysate-based in
vitro translation assay. The lysate was treated with different
concentrations of the native toxin and the deleted variants, and
the translation of endogenous globin mRNA was assayed.
Inhibition of protein synthesis was measured as decrease in
incorporation of [3H]leucine in the nascent polypeptides
synthesized. Restrictocin caused a dose-dependent inhibition
of protein synthesis with an ID50 of 8 ng´mL
21 (Table 2). The
mutants D1±8 and D1±15 were partially active with respective
ID50 values of 49 ng´mL
21 and 290 ng mL21, however, the
mutant D1±30 was completely inactive (Table 2). The mutant
D146±149 was about three times less active compared to the
native toxin with an ID50 of 23 ng´mL
21, while the mutants
D139±149 and D144±149 were completely inactive mani-
festing no inhibition of protein synthesis even upto
1000 ng´mL21 (Table 2).
Effect of deletions on the cytotoxic activity of restrictocin on
HeLa cells
Restrictocin and its mutants were tested for their cytotoxic
activity on HeLa cells permeabilized by infection with
adenovirus. The decrease in incorporation of [3H]leucine in
the newly synthesized cellular proteins was taken as the
measure of the cytotoxicity. None of the N- or C-terminal
deletion mutants showed any cytotoxic activity, while the full
length toxin showed a dose dependent cytotoxicity in this assay.
The deletion mutants were completely inactive, as even with
100 mg´mL21 they did not produce 50% inhibition of cellular
protein synthesis as compared to the native toxin which had an
ID50 of 2 mg´mL
21 (Table 2).
Stability of proteins in in vitro translation assay
To investigate if the loss of enzymatic activity observed in the
deletion mutants of restrictocin was a reflection of an increased
proteolytic degradation, various proteins were incubated with
rabbit reticulocyte lysate for 1 h at 30 8C. At the end of the
Fig. 4. Specific ribonucleolytic activity of
restrictocin and mutants on 28S rRNA.
Rabbit reticulocyte lysate was treated with
various mutants of restrictocin at the indicated
protein concentrations. The reaction was
carried out in 40 mm Tris/HCl, pH 7.5, buffer
containing 10 mm EDTA at 37 8C for 15 min
followed by termination of reaction using
0.4% SDS. Total RNA was extracted and
resolved by electrophoresis on a 2%
agarose gel.
Table 2. Effect of N- and C-terminal deletions on in vitro protein
synthesis inhibitory activity, and cytotoxic activity of restrictocin A.
Rabbit reticulocyte lysate was treated with various concentrations of
deletion mutants of restrictocin at 30 8C for 1 h. B. HeLa cells were
infected with adenovirus and treated with different concentrations of the
toxin and mutants. Incorporation of [3H]leucine in the newly synthesized
proteins was measured. ID50 refers to the amount of toxin required to inhibit
protein synthesis by 50%.
ID50
Inhibition of in vitro translation Cytotoxic activity
Protein (ng´mL21) (pm) (mg´mL21) (nm)
D1±8 49 3159 .100 .6447
D1±15 290 19674 .100 .6784
D1±30 .1000 .76390 .100 .7639
D146±149 23 1442 .100 .6269
D144±149 .1000 .63570 .100 .6357
D139±149 .1000 .65870 .100 .6587
Restrictocin 8 476 2 119
Fig. 5. Effect of rabbit reticulocyte lysate on the integrity of restrictocin
and mutants. Restrictocin and its deletion mutants (5 mg) were incubated
at 30 8C for 1 h with rabbit reticulocyte lysate followed by immunopre-
cipitation with an antirestrictocin antibody. The precipitated proteins were
separated by SDS/PAGE on a 14% gel and analysed by Western blotting.
Lanes 1, restrictocin; 2, D1±8; 3, D1±15; 4, D1±30; 5, D146±149; 6,
D144±149; 7, D139±149; 8, none. The arrowhead marks the location of the
proteins of interest. Molecular mass markers have been shown in kDa.
1782 S. K. Nayak et al. (Eur. J. Biochem. 267) q FEBS 2000
incubation the proteins were immunoprecipitated and
visualized by Western blotting. As shown in Fig. 5, all mutants
were found to be intact and the amounts recovered were
comparable to that of the native protein treated similarily.
D I S C U S S I O N
The study shows that small deletions of eight amino acids from
the N-terminus or four amino acids from the C-terminus render
the toxin partially inactive. Any further deletions from either
ends resulted in the total inactivation of the toxin. D1±8 and
D146±149, although less active than the native protein, retained
the specific ribonucleolytic activity. The CD-spectral analysis
clearly demonstrates major alterations in the structure of D1±8,
however, the conformation of D146±149 was not altered
remarkably. Both of these deletion mutants are devoid of the
outer disulfide bond because of the respective deletions of Cys5
and Cys147 in D1±8 and D146±149. However, we have earlier
shown that individual mutations of Cys5 and Cys147 in
restrictocin do not affect the conformation and functional
activity of the protein [16]. Therefore, the loss of activity of
D1±8 and D146±149 does not appear to be an outcome of the
absence of Cys5±Cys147 disulfide bond.
The deletions in this study have been made from either N- or
C-terminus of restrictocin in order to localize the activity in the
molecule and also to investigate the importance of the termini
in the function of the toxin. All deletion mutants had all the
putative active site residues intact. In the in vitro translation
assay, various mutant proteins were found to be intact at the end
of the incubation, suggesting that the loss of enzymatic activity
is not a consequence of relatively increased degradation of
these proteins during the assay. The loss of activity observed
appears to be a reflection of structural perturbations. The
deletions that retain the partial activity of the toxin are those
that remove partly b1 (D1±8) and b7 (D146±149), respectively,
from the N- and C-terminal ends of restrictocin. Further
deletions from the N-terminus deleting b1 + L1 (D1±15) and
b1, L1 + b2 (D1±30) or from C-terminus totally deleting b7
(D144±149) and b7 + L6 (D139±149) apparently produce a
total collapse of restrictocin structure. Kao and Davies [19]
have proposed that there is hydrogen bond formation between
amino-acid residues in b1 and b2 with residues in b6 and hence
deletion of residues from this region causes loss of catalytic
activity of mitogillin. The loss of restrictocin function arising
out of the small deletions may possibly be due to the collapse of
such hydrogen bonded links that usually contribute to
maintaining an active conformation even in the absence of
the outer disulfide bond. It is quite evident that the amino-acid
sequences at both ends of restrictocin are extremely crucial
in maintaining an enzymatically active conformation of the
toxin. The C-terminus seems relatively more crucial than the
N-terminus as comparatively smaller deletions on the carboxyl
end make the toxin partially inactive.
The role of the termini in the structure and function of
different ribonucleases has been studied quite extensively. The
N-terminal sequence of bovine RNase A known as S-peptide,
consisting of 20 amino-acid residues, contributes to the
maintenance of the structure of the rest of the molecule called
S-protein [34]. The side chain of Phe 8 in S-peptide has been
found to contribute to the stabilization of the transition state of
the complex between S-peptide and S-protein that gives rise to
the stability of RNase S [35]. A deletion of seven amino-acid
residues from the N-terminal end of human pancreatic
ribonuclease destabilizes the folded structure of the RNase
molecule and the truncated molecule was found to retain some
ribonuclease as well as RNase inhibitor binding ability [36].
The C-terminal end tetrapeptide sequence EDST has been
found not to be essential for the ribonuclease activity of human
pancreatic ribonuclease but the deletion of the four amino acids
seems to increase the thermal stability of the enzyme [37]. The
C-terminal EDST extension in human pancreatic ribonuclease
has been proposed to be destabilizing the C-terminal helix and
that its deletion may facilitate efficient folding of the molecule
[37]. It appears that both the N- and C-termini in restrictocin
are contributing towards the folding of the molecule to attain an
active conformation.
In conclusion, the current study has shown that intact N- and
C-termini are extremely crucial for retaining the enzymatically
active conformation of restrictocin. Although the putative
active site residues of this unique ribonuclease are quite far
from both the termini, and an intact Cys5±Cys147 disulfide
bond connecting the two termini is not essential for its activity,
yet the two termini seem to play an important role in
maintaining its functionally active conformation.
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